Enrico Arosio

Enrico Arosio

Auto-generated profile, based on publicly available information

Enrico Arosio

University of Verona, Verona, Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1991 in Angiology
Verified
Journal Article
Closed access
EAEnrico Arosio
Enrico Arosio
GMGermana Montesi
Germana Montesi
MZMassimo Zannoni
Massimo Zannoni
Luigi PerbelliniLuigi Perbellini
Luigi Perbellini
FPFrancesca Paluani
Francesca Paluani
ALAlessandro Lechi
Alessandro Lechi
After a two-week washout (WO) period with placebo 1 capsule/ bid, 12 patients suffering from stable Raynaud's phenomenon were treated with ketanserin (K) 40 mg/ bid for fifteen days. Blood pressure, heart rate, and laboratory parameters were evaluated at the end of each period. Patients used diary cards to record the number, duration, and intensity of attacks. Computerized thermometry of the fingers was evaluated at basal temperature after acclimatization, 23°C for thirty minutes; after cold test, 10°C for five minutes; and after thermal recovery, 23°C for eighteen minutes. Results were analyzed statistically by use of Student's t-test for paired data (p<0.05). No marked changes were observed in the symptoms of the attacks, but K proved effective in significantly reducing the number and duration of daily attacks and in promoting their spontaneous regression. Thermometry revealed a parallel increase in temperatures, particularly basal and recovery values. The data suggest increased flow and decreased vasospasm following 5-HT2 receptor blockade.

28 September 2020 in Ulyanovsk Medico-biological Journal
Verified
Journal Article
Closed access
LCLuca Costanzo
Luca Costanzo
SGSimona Antonina Grasso
Simona Antonina Grasso
FPFrancesco Paolo Palumbo
Francesco Paolo Palumbo
GAGiorgio Ardita
Giorgio Ardita
LPLuigi Di Pino
Luigi Di Pino
GFGiacomo Failla
Giacomo Failla
The development of coagulopathy is emerging as one of the most significant poor prognostic features in COVID-19 pneumopathy. Thromboembolic manifestations such as pulmonary embolism and disseminated intravascular coagulation (DIC) have been reported and resulted in poor prognosis for the patient. Starting from the evidence in the literature, the purpose of this paper is to analyze potential mechanism involved in coagulation impairment following COVID-19 infection and identify possible vascular therapeutic strategies. D-dimer, a protein product of fibrin degradation, has been found elevated in the most severe cases and correlated to mortality. Potentially involved factors in the impairment of coagulation caused by viral infection include the dysregulated inflammatory response, platelet and endothelial dysfunction with impaired fibrinolysis. Heparin is an anticoagulant molecule that also showed anti-inflammatory properties and a potential antiviral effect. A favorable outcome was highlighted with the use of LMWH in severe patients with COVID-19 who meet the SIC criteria (sepsis-induced coagulopathy) or with markedly high D-dimer. The use of low molecular weight heparin could prevent thromboembolic complications in COVID-19 pneumopathy. However, the correct timing of prophylaxis according to the stage of COVID-19 disease and the appropriate therapeutic dosage to use in severe cases need further researches. Keywords: COVID-19, pneumonia, thrombosis, coagulopathy, D-dimer, low molecular weight heparin. Одним из наиболее неблагоприятных прогностических признаков пневмопатии при COVID-19 является развитие коагулопатии. У пациентов с COVID-19 наблюдались признаки тромбоэмболии, например тромбоэмболия легочной артерии и ДВС-синдром, что негативно сказывалось на здоровье пациента. Целью исследования является анализ потенциального механизма нарушения свертывания крови у пациентов, перенесших COVID-19, и определение возможных терапевтических стратегий. Было обнаружено, что у пациентов с тяжелой формой заболевания уровень D-димера, белкового продукта распада фибрина, повышен и напрямую взаимосвязан со смертностью. К факторам, влияющим на нарушение коагуляции, вызванной вирусной инфекцией, относятся неуправляемый воспалительный процесс, тромбоцитарная и эндотелиальная дисфункция с нарушением фибринолиза. Гепарин, являясь прямым антикоагулянтом, также обладает противовоспалительными свойствами и выраженным противовирусным эффектом. Благоприятный исход наблюдался при использовании низкомолекулярного гепарина у тяжелых пациентов с COVID-19 с коагулопатией, вызванной сепсисом, или высоким уровнем D-димера. Использование низкомолекулярного гепарина может предотвратить тромбоэмболические осложнения пневмопатии у пациентов с COVID-19. Тем не менее точное время профилактики в зависимости от стадии заболевания COVID-19 и соответствующая терапевтическая дозировка, которая может быть использована в тяжелых случаях, требуют дальнейших исследований. Ключевые слова: COVID-19, пневмония, тромбоз, коагулопатия, D-димер, низкомолекулярный гепарин.

1 October 2005 in EP Europace
Verified
Journal Article
Open access
PDF file
JMJ. Makmur
J. Makmur
GBG.L. Bergandi
G.L. Bergandi
EAE. Arosio
E. Arosio
MIM. Ivaldi
M. Ivaldi
Initial energy (IE) of 200 J or greater is recommended for external electrical cardioversion (EC) of Atrial Fibrillation (AF) with monophasic waveform (MW). Devices that deliver current with a biphasic waveform (BW) appear to achieve EC at lower energy levels than that use a MW. The aim of the present study was to evaluate the influence of several factors (age, body-weight, ejection fraction, left atrial diameter, AF duration) on the results of EC with BW. 105 patients (pts) (59 male and 46 female, mean age 70 ± 8 yrs) underwent EC. Before EC, all pts were treated with oral anticoagulant for 4 weeks until the INR value achieved between 2.5 and 3, and with different antiarrhythmic drugs (sotalol, propafenone, flecainide, amiodarone). EC was done under general anaesthesia, in the presence of anaesthetist. The initial energy used for the first shock was 50 J/100 J, increasing up to 150-200 J, if the first shock unsuccessful (protocol 50/100J to 150-200 J). Reversion of AF to sinus rhythm was obtained in 92 % of the pts. Correlated with shock energy of 50 J, 100 J, 150 J, 200 J, the successful CE was found for the body-weight 69 ± 5, 70 ± 12, 78 ± 4 and 80 ± 9 kg, respectively. There was no statistical different between the four groups, regarding age, left atrial diameter, ventricular systolic function, duration of arrhythmia. In conclusion, an IE of 50 J could be used in pts weighing ⊂ 75 kg, an IE of 100 J could be used in pts with weight ⊇ 75 but ⊆ 82 kg, while for pts with a weight ⊃ 82 kg an IE of 150 J should be recommended.